Iñaki Gutiérrez-Ibarluzea

Prof. Iñaki Gutiérrez-Ibarluzea

Basque Foundation for Health Innovation and Research, Landa, Spain
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2022 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
SGSamuel Gidding
Samuel Gidding
AWAlbert Wiegman
Albert Wiegman
UGUrh Groselj
Urh Groselj
TFTomas Freiberger
Tomas Freiberger
NPNoel Peretti
Noel Peretti
MGMarius Geanta
Marius Geanta
Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe leading to significantly higher risk for premature heart disease in those affected. As treatment beginning early in life is highly effective in preventing heart disease and cost-effective in these patients, screening for FH is crucial. It has therefore now been recognized by the European Commission Public Health Best Practice Portal as an effective strategy. Model programmes exist in Europe to identify young individuals with FH, which are based on cascade screening of first-degree relatives of affected individuals, universal screening for high cholesterol, opportunistic screening of high-risk individuals, or a combination of the above approaches. Recommendations presented herein to improve identification of FH emphasize that every country should have an FH screening programme. These programmes should be adapted from existing strategies to best fit the individual country’s healthcare system, governments should provide financial support for these programmes and related care, and further research to optimize care and implementations should be conducted.

13 August 2013 in BMC Medicine
Verified
Journal Article
Open access
PDF file
BGBrian Godman
Brian Godman
AFAlexander E Finlayson
Alexander E Finlayson
PCParneet K Cheema
Parneet K Cheema
EZEva Zebedin-Brandl
Eva Zebedin-Brandl
IGIñaki Gutiérrez-Ibarluzea
Iñaki Gutiérrez-Ibarluzea
LGLars L Gustafsson
Lars L Gustafsson
Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

1 January 2013 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
RMRickard Malmstrom
Rickard Malmstrom
BGBrian Godman
Brian Godman
EDEduard Diogene
Eduard Diogene
CBChristoph Baumgärtel
Christoph Baumgärtel
MBMarion Bennie Marion Bennie
Marion Bennie Marion Bennie
LGLars L. Gustafsson
Lars L. Gustafsson
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination. Published studies have shown dabigatran to be cost-effective but there are budget concerns given the prevalence of AF. There are also issues with potentially re-designing anticoagulant services. This has resulted in activities across countries to better manage its use. Objective: To (i) review authority activities in over 30 countries and regions, (ii) use the findings to develop new models to better manage the entry of new drugs, and (iii) review the implications for all major stakeholder groups. Methodology: Descriptive review and appraisal of activities regarding dabigatran and the development of guidance for groups through an iterative process. Results: There has been a plethora of activities among authorities to manage the prescribing of dabigatran including extensive pre-launch activities, risk sharing arrangements, prescribing restrictions, and monitoring of prescribing post-launch. Reimbursement has been denied in some countries due to concerns with its budget impact and/or excessive bleeding. Development of a new model and future guidance is proposed to better manage the entry of new drugs, centering on three pillars of pre-, peri-, and post-launch activities. Conclusion: Models for introducing new drugs are essential to optimize their prescribing especially where there are concerns. Without such models, new drugs may be withdrawn prematurely and/or struggle for funding.

26 April 2023 in Frontiers in Public Health
Verified
Journal Article
Open access
AZAntal Zemplényi
Antal Zemplényi
KTKonstantin Tachkov
Konstantin Tachkov
LBLaszlo Balkanyi
Laszlo Balkanyi
BNBertalan Németh
Bertalan Németh
ZPZsuzsanna Ida Petykó
Zsuzsanna Ida Petykó
ZKZoltán Kaló
Zoltán Kaló
Background: Artificial intelligence (AI) has attracted much attention because of its enormous potential in healthcare, but uptake has been slow. There are substantial barriers that challenge health technology assessment (HTA) professionals to use AI-generated evidence for decision-making from large real-world databases (e.g., based on claims data). As part of the European Commission-funded HTx H2020 (Next Generation Health Technology Assessment) project, we aimed to put forward recommendations to support healthcare decision-makers in integrating AI into the HTA processes. The barriers, addressed by the paper, are particularly focusing on Central and Eastern European (CEE) countries, where the implementation of HTA and access to health databases lag behind Western European countries.Methods: We constructed a survey to rank the barriers to using AI for HTA purposes, completed by respondents from CEE jurisdictions with expertise in HTA. Using the results, two members of the HTx consortium from CEE developed recommendations on the most critical barriers. Then these recommendations were discussed in a workshop by a wider group of experts, including HTA and reimbursement decision-makers from both CEE countries and Western European countries, and summarized in a consensus report.Results: Recommendations have been developed to address the top 15 barriers in areas of (1) human factor-related barriers, focusing on educating HTA doers and users, establishing collaborations and best practice sharing; (2) regulatory and policy-related barriers, proposing increasing awareness and political commitment and improving the management of sensitive information for AI use; (3) data-related barriers, suggesting enhancing standardization and collaboration with data networks, managing missing and unstructured data, using analytical and statistical approaches to address bias, using quality assessment tools and quality standards, improving reporting, and developing better conditions for the use of data; and (4) technological barriers, suggesting sustainable development of AI infrastructure.Conclusion: In the field of HTA, the great potential of AI to support evidence generation and evaluation has not yet been sufficiently explored and realized. Raising awareness of the intended and unintended consequences of AI-based methods and encouraging political commitment from policymakers is necessary to upgrade the regulatory and infrastructural environment and knowledge base required to integrate AI into HTA-based decision-making processes better.

27 August 2010 in British Journal of Nutrition
Verified
Journal Article
Open access
PDF file
ILI. Lenoir-Wijnkoop
I. Lenoir-Wijnkoop
MDM. Dapoigny
M. Dapoigny
DDD. Dubois
D. Dubois
EGE. van Ganse
E. van Ganse
IGIñaki Gutiérrez-Ibarluzea
Iñaki Gutiérrez-Ibarluzea
MNM. J. C. Nuijten
M. J. C. Nuijten
There is a new merging of health economics and nutrition disciplines to assess the impact of diet on health and disease prevention and to characterise the health and economic aspects of specific changes in nutritional behaviour and nutrition recommendations. A rationale exists for developing the field of nutrition economics which could offer a better understanding of both nutrition, in the context of having a significant influence on health outcomes, and economics, in order to estimate the absolute and relative monetary impact of health measures. For this purpose, an expert meeting assessed questions aimed at clarifying the scope and identifying the key issues that should be taken into consideration in developing nutrition economics as a discipline that could potentially address important questions. We propose a first multidisciplinary outline for understanding the principles and particular characteristics of this emerging field. We summarise here the concepts and the observations of workshop participants and propose a basic setting for nutrition economics and health outcomes research as a novel discipline to support nutrition, health economics and health policy development in an evidence and health-benefit-based manner.

18 November 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
TGThe DISCHARGE Trial Group
The DISCHARGE Trial Group
ANAdriane E. Napp
Adriane E. Napp
RHRobert Haase
Robert Haase
MLMichael Laule
Michael Laule
GSGeorg M. Schuetz
Georg M. Schuetz
MDMarc Dewey
Marc Dewey